Literature DB >> 25710950

Infection and medication-related osteonecrosis of the jaw.

H Katsarelis1, N P Shah1, D K Dhariwal1, M Pazianas2.   

Abstract

Medication-related osteonecrosis of the jaw (MRONJ), although initially believed to be exclusively associated with bisphosphonates, has been implicated in recent reports with additional drugs, especially the bone antiresorptive denosumab. The pathophysiology has not been fully elucidated, and no causal association between bone antiresorptive regimens and MRONJ has yet been established. However, reduced bone turnover and infection, an almost universal finding, are thought to be central to the pathogenesis of MRONJ. Both bisphosphonates and denosumab, through different pathways of action, significantly reduce the rate of bone turnover and potentially reduce the efficacy of the host defense against infection. Recent evidence questions the simplified etiology of low bone turnover causing MRONJ and offers evidence on the prominent role of infection instead. The management of MRONJ remains a significant clinical challenge, with little progress having been made on treatment. The aim of this article is to explore the current theories on the etiology of MRONJ and to emphasize the importance of infection in the development of this devastating pathology. © International & American Associations for Dental Research 2015.

Entities:  

Keywords:  antiangiogenic effects; bisphosphonates; denosumab; low bone turnover; macrophages; osteonecrosis of the jaw

Mesh:

Substances:

Year:  2015        PMID: 25710950     DOI: 10.1177/0022034515572021

Source DB:  PubMed          Journal:  J Dent Res        ISSN: 0022-0345            Impact factor:   6.116


  40 in total

1.  A potential osteoporosis target in the FAS ligand/FAS pathway of osteoblast to osteoclast signaling.

Authors:  Daniel R Jones
Journal:  Ann Transl Med       Date:  2015-08

Review 2.  Osteonecrosis of the jaw (ONJ): diagnosis and management in 2015.

Authors:  A Khan; A Morrison; A Cheung; W Hashem; J Compston
Journal:  Osteoporos Int       Date:  2015-10-22       Impact factor: 4.507

3.  Medication-related osteonecrosis of the jaw after tooth extraction in cancer patients: a multicenter retrospective study.

Authors:  T Hasegawa; S Hayashida; E Kondo; Y Takeda; H Miyamoto; Y Kawaoka; N Ueda; E Iwata; H Nakahara; M Kobayashi; S Soutome; S I Yamada; I Tojyo; Y Kojima; M Umeda; S Fujita; H Kurita; Y Shibuya; T Kirita; T Komori
Journal:  Osteoporos Int       Date:  2018-11-07       Impact factor: 4.507

4.  Indigenous Microbiota Protects against Inflammation-Induced Osteonecrosis.

Authors:  D W Williams; H E Vuong; S Kim; A Lenon; K Ho; E Y Hsiao; E C Sung; R H Kim
Journal:  J Dent Res       Date:  2020-02-28       Impact factor: 6.116

Review 5.  Osteonecrosis of the Jaw-a Bone Site-Specific Effect of Bisphosphonates.

Authors:  Jenny A F Vermeer; Greetje A P Renders; Vincent Everts
Journal:  Curr Osteoporos Rep       Date:  2016-10       Impact factor: 5.096

6.  Increased CD14+ and decreased CD14- populations of monocytes 48 h after zolendronic acid infusion in breast cancer patients.

Authors:  A Kyrgidis; M P Yavropoulou; R Lagoudaki; C Andreadis; K Antoniades; D Kouvelas
Journal:  Osteoporos Int       Date:  2016-11-17       Impact factor: 4.507

7.  Uncommon presentation of medication-related osteonecrosis of the mandible in a patient with metastatic prostate cancer.

Authors:  Meera Thavarajah; Rahul Jayaram
Journal:  BMJ Case Rep       Date:  2019-02-26

8.  Rheumatoid Arthritis Exacerbates the Severity of Osteonecrosis of the Jaws (ONJ) in Mice. A Randomized, Prospective, Controlled Animal Study.

Authors:  Rafael Scaf de Molon; Chingyun Hsu; Olga Bezouglaia; Sarah M Dry; Flavia Q Pirih; Akrivoula Soundia; Fernando Queiroz Cunha; Joni Augusto Cirelli; Tara L Aghaloo; Sotirios Tetradis
Journal:  J Bone Miner Res       Date:  2016-05-04       Impact factor: 6.741

Review 9.  Chemical and Radiation-Associated Jaw Lesions.

Authors:  Temitope T Omolehinwa; Sunday O Akintoye
Journal:  Dent Clin North Am       Date:  2016-01

10.  Denosumab: a case of MRONJ with resolution.

Authors:  C V Lyttle; H Patterson
Journal:  Br Dent J       Date:  2016-06-24       Impact factor: 1.626

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.